Literature DB >> 20080469

Supportive care for patients with early breast cancer.

Laura García-Estévez1, Ignasi Tusquets, Isabel Alvarez, César Rodríguez, Yolanda Fernández, Miguel Angel Seguí, Jesús García-Mata, Ana Lluch.   

Abstract

Breast cancer treatment currently requires the joint efforts of a multidisciplinary team to effectively combine chemotherapy, hormone therapy, biological agents, surgery and radiation therapy when needed. To develop such a treatment plan, it is important to know the benefits as well as the potential toxic effects of each therapy. Thus, many patients with early breast cancer complain of collateral adverse events such as fatigue, nausea, vomiting, loss of libido, hot flashes, night sweats or neuropathy due to the complex therapies they are receiving. To date, the treatment of such symptoms is an important issue that greatly affects the quality of life of these patients. In this review, we report the content of a multi-expert meeting where the incidence of and medical approach to some of the most common adverse events encountered during the treatment of patients with early breast cancer were analysed.

Entities:  

Mesh:

Year:  2010        PMID: 20080469     DOI: 10.1007/s12094-010-0464-1

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  113 in total

1.  Breast cancer trial with erythropoietin terminated unexpectedly.

Authors:  Brian Leyland-Jones
Journal:  Lancet Oncol       Date:  2003-08       Impact factor: 41.316

2.  Effective interventions for CINV: NCCN Antiemesis Clinical Practice Guidelines in Oncology.

Authors: 
Journal:  ONS News       Date:  2004

3.  Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.

Authors:  Siu-Fun Wong; Holly O Chan
Journal:  Pharmacotherapy       Date:  2005-03       Impact factor: 4.705

4.  Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference.

Authors:  F Roila; P J Hesketh; J Herrstedt
Journal:  Ann Oncol       Date:  2005-11-28       Impact factor: 32.976

Review 5.  Chemotherapy-induced neuropathy.

Authors:  Anthony J Windebank; Wolfgang Grisold
Journal:  J Peripher Nerv Syst       Date:  2008-03       Impact factor: 3.494

6.  Measuring the side effects of taxane therapy in oncology: the functional assesment of cancer therapy-taxane (FACT-taxane).

Authors:  David Cella; Amy Peterman; Stacie Hudgens; Kimberly Webster; Mark A Socinski
Journal:  Cancer       Date:  2003-08-15       Impact factor: 6.860

7.  A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre.

Authors:  A Molassiotis; M P Saunders; J Valle; G Wilson; P Lorigan; A Wardley; E Levine; R Cowan; J Loncaster; C Rittenberg
Journal:  Support Care Cancer       Date:  2007-10-10       Impact factor: 3.603

Review 8.  Quality of life and symptom measures in oncology: an overview.

Authors:  Mehul K Soni; David Cella
Journal:  Am J Manag Care       Date:  2002-12       Impact factor: 2.229

9.  The prevalence and correlates of fatigue in patients receiving treatment with chemotherapy and radiotherapy. A comparison with the fatigue experienced by healthy individuals.

Authors:  D Irvine; L Vincent; J E Graydon; N Bubela; L Thompson
Journal:  Cancer Nurs       Date:  1994-10       Impact factor: 2.592

10.  Anemia in oncology practice: relation to diseases and their therapies.

Authors:  Faruk Tas; Yesim Eralp; Mert Basaran; Burak Sakar; Suleyman Alici; Andac Argon; Gulistan Bulutlar; Hakan Camlica; Adnan Aydiner; Erkan Topuz
Journal:  Am J Clin Oncol       Date:  2002-08       Impact factor: 2.339

View more
  2 in total

Review 1.  Breast cancer medications and vision: effects of treatments for early-stage disease.

Authors:  Alvin Eisner; Shiuh-Wen Luoh
Journal:  Curr Eye Res       Date:  2011-08-05       Impact factor: 2.424

2.  Barrier protective use of skin care to prevent chemotherapy-induced cutaneous symptoms and to maintain quality of life in patients with breast cancer.

Authors:  Johannes Wohlrab; Nikola Bangemann; Anke Kleine-Tebbe; Marc Thill; Sherko Kümmel; Eva-Maria Grischke; Rainer Richter; Sophie Seite; Diana Lüftner
Journal:  Breast Cancer (Dove Med Press)       Date:  2014-08-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.